UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 6, 2010
NABI BIOPHARMACEUTICALS
(Exact Name of Registrant as specified in its charter)
Delaware |
000-04829 | 59-1212264 | ||
(State or Other Jurisdiction of |
(Commission File Number) | (IRS Employer Identification No.) |
12276 Wilkins Avenue, Rockville, Maryland 20852
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (301) 770-3099
Not Applicable
(Registrant’s name or former address, if change since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition
On May 6, 2010, Nabi Biopharmaceuticals (the “Company”) issued a press release announcing its results of operations for the three months ended March 27, 2010. A copy of the press release announcing these results is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits
Exhibit |
Description | |
99.1 | Earnings Press Release |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
NABI BIOPHARMACEUTICALS | ||
By: | /s/ Raafat E.F. Fahim, Ph.D. | |
Raafat E.F. Fahim, Ph.D. | ||
President and Chief Executive Officer |
Date: May 6, 2010